EULAR Lupus Nephritis Trials Network Study Group The

EULAR Lupus Nephritis Trials Network Study Group The mission of the Lupus Nephritis Trials Network (LNTN) is to improve outcomes for patients with lupus nephritis through i): the conduct of clinical trials designed to prevent chronic kidney disease and end-stage kidney failure; and ii): the development of clinical trial methodologies that improve and simplify the assessment of therapeutic agents. The network involves more than 200 members across 40 countries Project 1 – Outcome measures in lupus nephritis trials to identify early prognostic markers of longterm outcome via trial data, real life cohorts and a prospective registry. Mackay M. et al. , Arthritis Rheumatol 2019; 71: 411 -419. Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes. Project 2 – CALIBRATE trial to study autoreactive B cell reconstitution after rituximab, cyclophosphamide and steroids, alone or followed by belimumab. Aranow C. et al. Phase 2 trial of induction therapy with anti-CD 20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis. Abstract 607051 - Lupus 2019 Conference (San Francisco, USA). Project 3 – Repeat per protocol renal biopsy study to correlate clinical and immunological responses. F. Tamirou, I. Parodis, J. Menke, HJ Anders and FA Houssiau.